As of 2026-05-26, the Relative Valuation of Lyra Therapeutics Inc (LYRA) is (226.04) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.50 USD, the upside of Lyra Therapeutics Inc based on Relative Valuation is -45764.9%.
The range of the Relative Valuation is (239.40) - (222.98) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.5x - 22.9x | 20.0x |
| Forward P/E multiples | 15.3x - 18.2x | 16.9x |
| Fair Price | (239.40) - (222.98) | (226.04) |
| Upside | -48462.7% - -45146.1% | -45764.9% |
| Date | P/E |
| 2026-05-22 | -0.06 |
| 2026-05-21 | -0.06 |
| 2026-05-20 | -0.06 |
| 2026-05-19 | -0.06 |
| 2026-05-18 | -0.05 |
| 2026-05-15 | -0.06 |
| 2026-05-14 | -0.06 |
| 2026-05-13 | -0.06 |
| 2026-05-12 | -0.06 |
| 2026-05-11 | -0.06 |
| 2026-05-08 | -0.06 |
| 2026-05-07 | -0.06 |
| 2026-05-06 | -0.06 |
| 2026-05-05 | -0.06 |
| 2026-05-04 | -0.06 |
| 2026-05-01 | -0.06 |
| 2026-04-30 | -0.06 |
| 2026-04-29 | -0.06 |
| 2026-04-28 | -0.06 |
| 2026-04-27 | -0.06 |
| 2026-04-24 | -0.06 |
| 2026-04-23 | -0.06 |
| 2026-04-22 | -0.06 |
| 2026-04-21 | -0.06 |
| 2026-04-20 | -0.06 |
| 2026-04-17 | -0.07 |
| 2026-04-16 | -0.05 |
| 2026-04-15 | -0.05 |
| 2026-04-14 | -0.05 |
| 2026-04-13 | -0.05 |
| 2026-04-10 | -0.05 |
| 2026-04-09 | -0.04 |
| 2026-04-08 | -0.04 |
| 2026-04-07 | -0.04 |
| 2026-04-06 | -0.04 |
| 2026-04-02 | -0.04 |
| 2026-04-01 | -0.04 |
| 2026-03-31 | -0.04 |
| 2026-03-30 | -0.04 |
| 2026-03-27 | -0.04 |
| 2026-03-26 | -0.04 |
| 2026-03-25 | -0.04 |
| 2026-03-24 | -0.04 |
| 2026-03-23 | -0.03 |
| 2026-03-20 | -0.04 |
| 2026-03-19 | -0.04 |
| 2026-03-18 | -0.04 |
| 2026-03-17 | -0.04 |
| 2026-03-16 | -0.04 |
| 2026-03-13 | -0.11 |